Related references
Note: Only part of the references are listed.Enhanced cellular uptake and in vitro antitumor activity of short-chain fatty acid acylated daunorubicin-GnRH-III bioconjugates
Rozsa Hegedues et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2012)
In vitro degradation and antitumor activity of oxime bond-linked daunorubicin-GnRH-III bioconjugates and DNA-binding properties of daunorubicin-amino acid metabolites
Erika Orban et al.
AMINO ACIDS (2011)
Anthracycline-GnRH derivative bioconjugates with different linkages: Synthesis, in vitro drug release and cytostatic effect
Pascal Schlage et al.
JOURNAL OF CONTROLLED RELEASE (2011)
Development of an Oxime Bond Containing Daunorubicin-Gonadotropin-Releasing Hormone-III Conjugate as a Potential Anticancer Drug
Ildiko Szabo et al.
BIOCONJUGATE CHEMISTRY (2009)
GnRH-II Antagonists Induce Apoptosis in Human Endometrial, Ovarian, and Breast Cancer Cells via Activation of Stress-induced MAPKs p38 and JNK and Proapoptotic Protein Bax
Stefanie Fister et al.
CANCER RESEARCH (2009)
Type I Gonadotropin-Releasing Hormone Receptor Mediates the Antiproliferative Effects of GnRH-II on Prostate Cancer Cells
Marina Montagnani Marelli et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
New Derivatives of GnRH as Potential Anticancer Therapeutic Agents
Gabor Mezo et al.
CURRENT MEDICINAL CHEMISTRY (2008)
Gonadotropin-releasing hormone: GnRH receptor signaling in extrapituitary tissues
Lydia W. T. Cheung et al.
FEBS JOURNAL (2008)
Diversity of actions of GnRHs mediated by ligand-induced selective signaling
Robert P. Millar et al.
FRONTIERS IN NEUROENDOCRINOLOGY (2008)
Gonadotropin-releasing hormone analog structural determinants of selectivity for inhibition of cell growth: Support for the concept of ligand-induced selective signaling
Rakel Lopez de Maturana et al.
MOLECULAR ENDOCRINOLOGY (2008)
Plasma membrane expression of GnRH receptors: regulation by antagonists in breast, prostate, and gonadotrope cell lines
Ann R. Finch et al.
JOURNAL OF ENDOCRINOLOGY (2008)
Gonadotropin-releasing hormone type II antagonists induce apoptotic cell death in human endometrial and ovarian cancer cells in vitro and in vivo
Stefanie Fister et al.
CANCER RESEARCH (2007)
Targeted therapy of breast and gynecological cancers with cytotoxic analogues of peptide hormones
Joerg B. Engel et al.
MOLECULAR PHARMACEUTICS (2007)
Targeting of cytotoxic luteinizing hormone-releasing hormone analogs to breast, ovarian, endometrial, and prostate cancers
A Nagy et al.
BIOLOGY OF REPRODUCTION (2005)
Analogs of GnRH-I and GnRH-II inhibit epidermal growth factor-induced signal transduction and resensitize resistant human breast cancer cells to 40H-tamoxifen
AR Günthert et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2005)
Receptors for luteinizing hormone releasing hormone (LHRH) expressed in human non-Hodgkin's lymphomas can be targeted for therapy with the cytotoxic LHRH analogue AN-207
G Keller et al.
EUROPEAN JOURNAL OF CANCER (2005)
Human malignant melanomas express receptors for luteinizing hormone releasing hormone allowing targeted therapy with cytotoxic luteinizing hormone releasing hormone analogue
G Keller et al.
CANCER RESEARCH (2005)
Effective treatment of experimental human endometrial cancers with targeted cytotoxic luteinizing hormone-releasing hormone analogues AN-152 and AN-207
JB Engel et al.
FERTILITY AND STERILITY (2005)
Extracellular signal-regulated protein kinase, but not c-JunN-terminal kinase, is activated by type II gonadotropin-releasing hormone involved in the inhibition of ovarian cancer cell proliferation
KY Kim et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
Gonadotropin-releasing hormone receptors
RP Millar et al.
ENDOCRINE REVIEWS (2004)
Signaling and antiproliferative effects of type I and II gonadotropin-releasing hormone receptors in breast cancer cells
AR Finch et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
Chemotherapy targeted to cancers through tumoral hormone receptors
AV Schally et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2004)
Antiproliferative effects of the GnRH antagonist cetrorelix and of GnRH-II on human endometrial and ovarian cancer cells are not mediated through the GnRH type I receptor
C Gründker et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2004)
Type II gonadotropin-releasing hormone stimulates p38 mitogen-activated protein kinase and apoptosis in ovarian cancer cells
KY Kim et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
Peptide receptors as molecular targets for cancer diagnosis and therapy
JC Reubi
ENDOCRINE REVIEWS (2003)
New approaches to treatment of various cancers based on cytotoxic analogs of LHRH, somatostatin and bombesin
AV Schally et al.
LIFE SCIENCES (2003)
GnRH II and type II GnRH receptors
RP Millar
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2003)
Antitumor effects of the cytotoxic luteinizing hormone-releasing hormone analog AN-152 on human endometrial and ovarian cancers xenografted into nude mice
C Gründker et al.
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY (2002)
Differential expression of human gonadotropin-releasing hormone receptor gene in pituitary and ovarian cells
SK Kang et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2000)
High incidence of receptors for luteinizing hormone-releasing hormone (LHRH) and LHRH receptor gene expression in human prostate cancers
G Halmos et al.
JOURNAL OF UROLOGY (2000)
Stability of cytotoxic luteinizing hormone-releasing hormone conjugate (AN-152) containing doxorubicin 14-O-hemiglutarate in mouse and human serum in vitro:: Implications for the design of preclinical studies
A Nagy et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Share Paper
